Lung Cancer Clinical Trials in Chicago

Showing 381-400 of 784 trials

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

NCT04676386

This Observational study will explore the utility of the Biodesix, Inc. "PIR" (primary immune response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor proportion score (TPS) \> 50% and ECOG performance status (PS) 0-2 NSCLC patients who are treated with PD-1/PD-L1 based therapy with or without the addition of platinum based chemotherapy.

NSCLC Stage IVNSCLC, Stage IIIC

Addario Lung Cancer Medical Institute29 participantsStarted Feb 2021

San Carlos, California, United States • Chicago, Illinois, United States

TERMINATEDPhase 12.2 miles

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).

Non-Small Cell Lung CancerOvarian CancerFallopian Tube Cancer+3 more

Kite, A Gilead Company16 participantsStarted Oct 2019

Phoenix, Arizona, United States • Los Angeles, California, United States • Tampa, Florida, United States +7 more locations

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Lung Cancer Trials in Other Cities

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Prospective Clinicogenomic Program

The Lung Screening, Tobacco and Health Project

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Study of the CD40 Agonistic Monoclonal Antibody APX005M

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in Chicago